Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02250014 · ClinicalTrials.gov registry record · Phase 1
The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02250014 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 19 participants.
The verdict
NCT02250014, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This randomized pilot phase I trial studies how well sargramostim after cryotherapy works in treating patients with prostate cancer. Biological therapies, such as sargramostim, use substances made from living organisms that may stimulate the immune system in different ways and stop tumor cells from growing. Cryosurgery, also known as cryotherapy, kills tumor cells by freezing them. Giving sargramostim after cryotherapy may work better in treating prostate cancer.
Interventions
- BIOLOGICAL sargramostim
- PROCEDURE cryotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-10-05 |
| Est. Completion | 2020-12-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02250014
The ClinicalTrials.gov registry entry for NCT02250014 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sargramostim is the first listed.
NCT02250014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02250014 about?
NCT02250014 is a clinical study titled "The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer". This randomized pilot phase I trial studies how well sargramostim after cryotherapy works in treating patients with prostate cancer. Biological therapies, such as sargramostim, use substances made from living organisms that may stimulate the immune system in different ways and stop tumor cells from ...
What is the current status of trial NCT02250014?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2015-10-05. Estimated completion is 2020-12-21.
What interventions are being tested in trial NCT02250014?
The interventions under investigation include: sargramostim (BIOLOGICAL), cryotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT02250014?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.